Literature DB >> 24092682

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

Frank van den Hoogen1, Dinesh Khanna, Jaap Fransen, Sindhu R Johnson, Murray Baron, Alan Tyndall, Marco Matucci-Cerinic, Raymond P Naden, Thomas A Medsger, Patricia E Carreira, Gabriela Riemekasten, Philip J Clements, Christopher P Denton, Oliver Distler, Yannick Allanore, Daniel E Furst, Armando Gabrielli, Maureen D Mayes, Jacob M van Laar, James R Seibold, Laszlo Czirjak, Virginia D Steen, Murat Inanc, Otylia Kowal-Bielecka, Ulf Müller-Ladner, Gabriele Valentini, Douglas J Veale, Madelon C Vonk, Ulrich A Walker, Lorinda Chung, David H Collier, Mary Ellen Csuka, Barri J Fessler, Serena Guiducci, Ariane Herrick, Vivien M Hsu, Sergio Jimenez, Bashar Kahaleh, Peter A Merkel, Stanislav Sierakowski, Richard M Silver, Robert W Simms, John Varga, Janet E Pope.   

Abstract

OBJECTIVE: The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present work, by a joint committee of the ACR and the European League Against Rheumatism (EULAR), was undertaken for the purpose of developing new classification criteria for SSc.
METHODS: Using consensus methods, 23 candidate items were arranged in a multicriteria additive point system with a threshold to classify cases as SSc. The classification system was reduced by clustering items and simplifying weights. The system was tested by (1) determining specificity and sensitivity in SSc cases and controls with scleroderma-like disorders, and (2) validating against the combined view of a group of experts on a set of cases with or without SSc.
RESULTS: It was determined that skin thickening of the fingers extending proximal to the metacarpophalangeal joints is sufficient for the patient to be classified as having SSc; if that is not present, seven additive items apply, with varying weights for each: skin thickening of the fingers, fingertip lesions, telangiectasia, abnormal nailfold capillaries, interstitial lung disease or pulmonary arterial hypertension, Raynaud's phenomenon, and SSc-related autoantibodies. Sensitivity and specificity in the validation sample were, respectively, 0.91 and 0.92 for the new classification criteria and 0.75 and 0.72 for the 1980 ACR classification criteria. All selected cases were classified in accordance with consensus-based expert opinion. All cases classified as SSc according to the 1980 ACR criteria were classified as SSc with the new criteria, and several additional cases were now considered to be SSc.
CONCLUSIONS: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria for SSc and should allow for more patients to be classified correctly as having the disease.

Entities:  

Keywords:  Disease Activity; Systemic Sclerosis; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24092682     DOI: 10.1136/annrheumdis-2013-204424

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  500 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

Review 2.  Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors:  Oliver Distler; Antonio Cozzio
Journal:  Semin Immunopathol       Date:  2015-11-17       Impact factor: 9.623

3.  c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts.

Authors:  Elham Karimizadeh; Farhad Gharibdoost; Nasrin Motamed; Saeideh Jafarinejad-Farsangi; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Mol Cell Biochem       Date:  2015-04-16       Impact factor: 3.396

4.  Mosaic capillaroscopic findings in systemic sclerosis.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Wien Med Wochenschr       Date:  2018-02-01

5.  Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: a pilot study.

Authors:  Barbara Ruaro; Stefano Soldano; Vanessa Smith; Sabrina Paolino; Paola Contini; Paola Montagna; Carmen Pizzorni; Andrea Casabella; Samuele Tardito; Alberto Sulli; Maurizio Cutolo
Journal:  Rheumatol Int       Date:  2019-05-06       Impact factor: 2.631

Review 6.  Update on juvenile systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

7.  Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.

Authors:  Nezam Altorok; Pei-Suen Tsou; Patrick Coit; Dinesh Khanna; Amr H Sawalha
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

8.  Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.

Authors:  Rositsa Karalilova; Maria Kazakova; Tanya Sapundzhieva; Valentin Dichev; Zguro Batalov; Victoria Sarafian; Anastas Batalov
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

9.  Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features.

Authors:  Claudio Corallo; Antonella Fioravanti; Sara Tenti; Gianluca Pecetti; Ranuccio Nuti; Nicola Giordano
Journal:  Rheumatol Int       Date:  2019-08-01       Impact factor: 2.631

10.  Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.

Authors:  Ana C Medeiros-Ribeiro; Nadia E Aikawa; Carla G S Saad; Emily F N Yuki; Tatiana Pedrosa; Solange R G Fusco; Priscila T Rojo; Rosa M R Pereira; Samuel K Shinjo; Danieli C O Andrade; Percival D Sampaio-Barros; Carolina T Ribeiro; Giordano B H Deveza; Victor A O Martins; Clovis A Silva; Marta H Lopes; Alberto J S Duarte; Leila Antonangelo; Ester C Sabino; Esper G Kallas; Sandra G Pasoto; Eloisa Bonfa
Journal:  Nat Med       Date:  2021-07-30       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.